Shanghai Pharmaceuticals Holding Co., Ltd (SHPMF)
OTCMKTS
· Delayed Price · Currency is USD
1.562
-0.008 (-0.51%)
At close: Mar 17, 2025
SHPMF Revenue
In the year 2024, Shanghai Pharmaceuticals Holding had annual revenue of 275.25B CNY with 5.75% growth. Shanghai Pharmaceuticals Holding had revenue of 65.62B in the quarter ending December 31, 2024, with 4.52% growth.
Revenue
275.25B CNY
Revenue Growth
+5.75%
P/S Ratio
0.22
Revenue / Employee
5.57M CNY
Employees
49,402
Market Cap
8.27B USD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 275.25B | 14.96B | 5.75% |
| Dec 31, 2023 | 260.30B | 28.31B | 12.21% |
| Dec 31, 2022 | 231.98B | 16.16B | 7.49% |
| Dec 31, 2021 | 215.82B | 23.92B | 12.46% |
| Dec 31, 2020 | 191.91B | 5.34B | 2.86% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| SS Innovations International | 20.65M |
| Endo Inc. | 1.76B |
| Veradigm | 588.02M |
| Elite Pharmaceuticals | 70.00M |
| Northwest Biotherapeutics | 1.38M |
| Glass House Brands | 200.90M |
| BioStem Technologies | 301.83M |
| American Oncology Network | 1.76B |
Shanghai Pharmaceuticals Holding News
- 4 months ago - Chinese Cancer Drug Developer Hutchmed Sharpens R&D Focus, Divests Non-Core JV For Over $600 Million - Benzinga
- 4 months ago - HUTCHMED to divest 45% stake in JV with Shanghai Pharma - Seeking Alpha